Janssen makes Denmark a core country for clinical trials
US-based Janssen is pleased with the Danish health authorities, the qualifications of Danish doctors and researchers as well as the initiative Trial Nation – so pleased that the company has made Denmark one of its core countries for clinical trials, which means that the firm will increase its clinical activities in future.
BY ULRICH QUISTGAARD, TRANSLATED BY IDA LØJMAND
Janssen, the pharmaceutical unit of Johnson & Johnson, has appointed Denmark as a new core country for clinical trials.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
